A larger multicentric study with 152 AD patients showed that 12-week-long administration of MCT Ketasyn/AC-1202 (Cerecin), improved memory performance in APOE4(–), but not in APOE4(+) patients (Henderson et al., 2009; Henderson and Poirier, 2011). Here, APOE is linked to Alzheimer disease.